Physician profile
David Rushing
NPI 1760449540
$5,299.45
in general payments reported to CMS, 2019-2025
41 companies · $566 in 2025
The $566 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $308 · 2021: $1,017 · 2022: $957 · 2023: $1,053 · 2024: $566 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $669.48 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $468.76 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Axonics, INC. | $462.73 | 2022-2024 | Axonics, Bulkamid |
| Pfizer INC. | $456.73 | 2019-2024 | |
| Boston Scientific Corporation | $455.76 | 2019-2024 | Solyx Sis System |
| Aspira Women'S Health INC | $340.65 | 2021-2023 | Ova1 |
| Sumitomo Pharma America, INC. | $253.47 | 2023-2025 | Gemtesa, Myfembree |
| Channel Medsystems, INC. | $191.17 | 2022-2023 | |
| Sage Therapeutics, LLC | $152.35 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $141.10 | 2019-2025 | |
| Conmed Corporation | $130.30 | 2023 | Airseal |
| Stryker Corporation | $114.49 | 2019 | |
| Mayne Pharma Commercial LLC | $109.55 | 2021-2025 | |
| Myovant Sciences INC. | $107.23 | 2021-2022 | |
| Organon LLC | $105.98 | 2022-2025 | Nexplanon, Nuvaring, Jada System |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $104.14 | 2021-2023 | Da Vinci Surgical System |
| Exeltis, USA INC. | $96.11 | 2021-2024 | Slynd |
| Amgen INC. | $93.34 | 2019-2022 | |
| Daiichi Sankyo INC. | $87.80 | 2019-2021 | |
| Lupin INC. | $69.28 | 2019-2021 | |
| Urovant Sciences INC | $69.23 | 2021-2022 | |
| Therapeuticsmd, INC. | $67.80 | 2019-2022 | |
| Coopersurgical, INC. | $63.56 | 2019-2025 | Paragard T 380a |
| Scynexis, INC. | $53.26 | 2022 | |
| Millicent US INC | $52.02 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Becton, Dickinson and Company | $49.81 | 2022-2025 | Arista |
| Mylan Pharmaceuticals INC. | $42.34 | 2019-2022 | |
| Smith+Nephew, INC. | $39.44 | 2019-2022 | |
| Avion Pharmaceuticals | $36.26 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $30.45 | 2019 | |
| Evofem Biosciences, INC. | $24.78 | 2021 | |
| Dysis Medical, INC. | $22.50 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.46 | 2025 | Qelbree |
| Convatec INC. | $18.24 | 2022 | |
| Roche Diagnostics Corporation | $17.73 | 2020 | |
| Coloplast Corp | $16.44 | 2021 | |
| Meditrina | $16.07 | 2025 | |
| Merck Sharp & Dohme LLC | $13.83 | 2019 | |
| Novo Nordisk INC | $12.94 | 2020 | |
| Sanara Medtech INC. | $11.62 | 2020 | |
| Minerva Surgical, INC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.